CLSN - Celsion Corporation
| Previous Close | 1.7500 |
| Open | 1.7600 |
| Bid | 0.0000 x 1000 |
| Ask | 3.0000 x 800 |
| Day's Range | 1.7500 - 1.8212 |
| 52 Week Range | 1.3500 - 3.3400 |
| Volume | 73,087 |
| Avg. Volume | 139,079 |
| Market Cap | 36.459M |
| Beta (3Y Monthly) | 2.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5450 |
| Earnings Date | May 18, 2017 - May 19, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.50 |
- GlobeNewswire•6 days ago
Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands
Celsion Corporation (CLSN), an oncology drug-development company, announces that the University Medical Center Utrecht in the Netherlands has received Institutional Review Board (IRB) approval to begin a Phase I study to determine the safety, tolerability and feasibility of ThermoDox® (lyso-thermosensitive liposomal doxorubicin) in combination with Magnetic Resonance Guided High Intensity Focused Ultrasound (MR-HIFU) hyperthermia and cyclophosphamide therapy for the local treatment of the primary tumor in metastatic breast cancer (mBC).
- Thomson Reuters StreetEvents•28 days ago
Edited Transcript of CLSN earnings conference call or presentation 15-May-19 3:00pm GMT
Q1 2019 Celsion Corp Earnings Call
- ACCESSWIRE•last month
Celsion Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 15, 2019 / Celsion Corp. (NASDAQ: CLSN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 15, 2019 at 11:00 AM Eastern Time. ...
- GlobeNewswire•last month
Celsion Corporation Reports First Quarter 2019 Financial Results and Provides Business Update
Company to Hold Conference Call on Wednesday, May 15, 2019 at 11:00 a.m. EDT LAWRENCEVILLE, N.J, May 15, 2019 -- Celsion Corporation (NASDAQ: CLSN), an oncology drug.
- Zacks•last month
Is Celsion (CLSN) Stock Outpacing Its Medical Peers This Year?
Is (CLSN) Outperforming Other Medical Stocks This Year?
- Zacks•last month
Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates
Blueprint Medicines (BPMC) posts wider-than-expected loss in first-quarter while sales miss estimates.
- Zacks•2 months ago
Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
- Zacks•2 months ago
Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints
Puma Biotech (PBYI) incurs narrower loss in Q1. Sales of Nerlynx fall short of expectations due to higher discontinuations. Stock plunges 32.5%.
- Zacks•2 months ago
IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.
- Zacks•2 months ago
Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up
Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.
- Zacks•2 months ago
Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.
- GlobeNewswire•2 months ago
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
LAWRENCEVILLE, N.J., May 08, 2019 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.
- Zacks•2 months ago
Will Celsion (CLSN) Report Negative Earnings Next Week? What You Should Know
Celsion (CLSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•2 months ago
Celsion (CLSN) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Celsion (CLSN) closed at $2.19, marking a -1.79% move from the previous day.
- Zacks•2 months ago
Celsion (CLSN) Flat As Market Sinks: What You Should Know
Celsion (CLSN) closed at $2.20 in the latest trading session, marking no change from the prior day.
- Zacks•2 months ago
Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus
The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.
- Zacks•2 months ago
AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales
AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.
- Zacks•2 months ago
Is Celsion (CLSN) Outperforming Other Medical Stocks This Year?
Is (CLSN) Outperforming Other Medical Stocks This Year?
- Zacks•2 months ago
Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised
Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.
- Zacks•2 months ago
Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA
Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.
- GlobeNewswire•2 months ago
Celsion Corporation Announces Issuance of New Patent for ThermoDox®
Celsion Corporation (CLSN), a clinical stage oncology drug development company, today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 10,251,901 B2 – Thermosensitive Nanoparticle Formulations and Method of Making the Same, which is directly applicable to the method of treating cancer using a new ThermoDox® formulation. This new patent strengthens the coverage of ThermoDox®, Celsion’s heat-activated liposomal platform technology, currently in Phase III development for the treatment of primary liver cancer, also known as hepatocellular carcinoma (HCC). The Company’s pivotal 556-patient global Phase III OPTIMA Study in HCC completed enrollment in August 2018 at 65 clinical sites in North America, Europe, China, S. Korea, Taiwan, and Southeast Asia.
- Zacks•2 months ago
ProQR Initiates Dosing in Phase II/III Eye Disorder Study
ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
- GlobeNewswire•2 months ago
Celsion Corporation to Participate in Two Investor Conferences in May 2019
Company to Discuss its Ongoing Pivotal Phase III Study in Primary Liver Cancer and its Phase I/II Clinical Study in Ovarian Cancer LAWRENCEVILLE, N.J., April 12, 2019 --.
- GlobeNewswire•2 months ago
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
LAWRENCEVILLE, N.J., April 12, 2019 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.
- PR Newswire•2 months ago
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Celsion Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , April 11, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
